Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
10.85
-0.18 (-1.63%)
At close: Dec 5, 2025, 4:00 PM EST
10.88
+0.03 (0.28%)
After-hours: Dec 5, 2025, 7:56 PM EST
Omeros Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
202
Market Cap
769.27M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
OMER News
- 5 days ago - Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) - Business Wire
- 19 days ago - Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Omeros Corporation Reports Third Quarter 2025 Financial Results - Business Wire
- 25 days ago - Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 - Business Wire
- 7 weeks ago - Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting - Seeking Alpha
- 7 weeks ago - Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case - Seeking Alpha
- 7 weeks ago - Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group - Business Wire
- 7 weeks ago - A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? - The Motley Fool